BLAINJECTIONINJECTABLE
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
RUXIENCE (rituximab-pvvr) by Pfizer is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2019.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic monoclonal antibody approved by the FDA on July 23, 2019, for treatment of CD20-positive B-cell malignancies and certain autoimmune conditions. It is manufactured by Pfizer and represents a biosimilar alternative to the reference product RITUXAN (rituximab). The drug works by binding to CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity and direct apoptosis. RUXIENCE is positioned as a cost-competitive option within a mature market dominated by rituximab and next-generation CD20-targeting agents.
$0.0BPart D
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Pfizer is hiring 1 role related to this product
Worked on RUXIENCE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.